DZ2043A1 - Nouveaux dérivés. - Google Patents

Nouveaux dérivés.

Info

Publication number
DZ2043A1
DZ2043A1 DZ960087A DZ960087A DZ2043A1 DZ 2043 A1 DZ2043 A1 DZ 2043A1 DZ 960087 A DZ960087 A DZ 960087A DZ 960087 A DZ960087 A DZ 960087A DZ 2043 A1 DZ2043 A1 DZ 2043A1
Authority
DZ
Algeria
Prior art keywords
new derivatives
therapy
compositions
novel
derivatives
Prior art date
Application number
DZ960087A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ2043A1 publication Critical patent/DZ2043A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DZ960087A 1995-06-07 1996-06-05 Nouveaux dérivés. DZ2043A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47339695A 1995-06-07 1995-06-07
US63677996A 1996-04-19 1996-04-19

Publications (1)

Publication Number Publication Date
DZ2043A1 true DZ2043A1 (fr) 2002-10-23

Family

ID=27044121

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ960087A DZ2043A1 (fr) 1995-06-07 1996-06-05 Nouveaux dérivés.

Country Status (24)

Country Link
US (2) US5658903A (fr)
EP (2) EP1314728A1 (fr)
JP (1) JPH11513017A (fr)
KR (1) KR19990022574A (fr)
CN (1) CN1130358C (fr)
AT (1) ATE233561T1 (fr)
BR (1) BR9608591A (fr)
CA (1) CA2223533A1 (fr)
CZ (1) CZ392597A3 (fr)
DE (1) DE69626513T2 (fr)
DZ (1) DZ2043A1 (fr)
ES (1) ES2194106T3 (fr)
HU (1) HUP9802259A3 (fr)
IL (1) IL118544A (fr)
IN (1) IN186434B (fr)
MA (1) MA24242A1 (fr)
MY (1) MY114014A (fr)
NO (1) NO975716L (fr)
NZ (1) NZ311403A (fr)
PE (1) PE7798A1 (fr)
PL (1) PL185515B1 (fr)
TR (1) TR199701574T2 (fr)
TW (1) TW442481B (fr)
WO (1) WO1996040143A1 (fr)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
FI972970A7 (fi) * 1995-01-12 1997-09-11 Smithkline Beecham Corp Uusia yhdisteitä
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
PL187516B1 (pl) * 1996-01-11 2004-07-30 Smithkline Beecham Corp Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
WO1997032583A1 (fr) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Utilisations de composes csaidtm en tant qu'inhibiteurs de l'angiogenese
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1998007425A1 (fr) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Composes d'imidazole, compositions les contenant et leur utilisation
WO1998016230A1 (fr) * 1996-10-17 1998-04-23 Smithkline Beecham Corporation Procedes permettant d'inhiber de maniere reversible la myelopoiese dans des tissus mammaliens
ZA9711092B (en) * 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US6548512B1 (en) 1996-12-23 2003-04-15 Bristol-Myers Squibb Pharma Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
CA2294057A1 (fr) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Nouveaux composes de pyrazole et de pyrazoline substitues
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999001452A1 (fr) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Nouveaux imidazoles cycloalkyle-substitues
WO1999017776A1 (fr) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Nouveaux composes substitues de cycloalcenyle
EP1021173A1 (fr) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Emploi de composes de csaid?tm pour le traitement des contractions uterines
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
HUP0004947A2 (hu) * 1997-11-14 2002-03-28 Sankyo Co., Ltd. Piridilpirrol-származékok
WO1999032121A1 (fr) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
US6340685B1 (en) 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
JP2003525201A (ja) * 1998-08-20 2003-08-26 スミスクライン・ビーチャム・コーポレイション 新規な置換トリアゾール化合物
CA2342251A1 (fr) 1998-08-28 2000-03-09 Scios Inc. Inhibiteurs de p38-.alpha. kinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
AU6476599A (en) * 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
WO2000025791A1 (fr) * 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyrazines substitues pyridin-4-yle ou pyrimidin-4-yle
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (fr) * 1999-01-13 2000-07-20 Bayer Corporation DIPHENYLUREES A SUBSTITUANTS φ-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
MXPA01008440A (es) 1999-02-22 2002-04-24 Boehringer Ingelheim Pharma Derivados heterociclicos policiclos como agentes anti-inflamatorios..
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
NZ528846A (en) 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
WO2000055152A1 (fr) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Composes aromatiques heterocycliques utilises en tant qu'agents anti-inflammatoires
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
RU2278115C2 (ru) * 1999-05-21 2006-06-20 Сайос Инк. ПРОИЗВОДНЫЕ ИНДОЛЬНОГО РЯДА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
IL146309A (en) 1999-05-21 2008-03-20 Scios Inc Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US7122666B2 (en) * 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
AU7584500A (en) * 1999-09-17 2001-04-17 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
ATE311385T1 (de) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
EP1233951B1 (fr) * 1999-11-23 2005-06-01 SmithKline Beecham Corporation Composes de 3,4-dihydro-(1h)quinazolin-2-one utilises comme inhibiteurs de kinase csbp/p38
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ATE283048T1 (de) * 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
WO2001074821A1 (fr) * 2000-03-30 2001-10-11 Shionogi & Co., Ltd. Nouveau procede de production de derive d'imidazopyridine fondu et nouvelle forme cristalline
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2002005848A2 (fr) * 2000-07-13 2002-01-24 Pharmacia Corporation Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
ATE521353T1 (de) * 2000-10-23 2011-09-15 Glaxosmithkline Llc Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
WO2002044168A2 (fr) * 2000-11-20 2002-06-06 Scios Inc. Inhibiteurs de type indole de kinase p38
EP1341782A2 (fr) 2000-11-20 2003-09-10 Scios Inc. Inhibiteurs de la kinase p38
DE60125980T2 (de) 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2437248A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
CA2440211A1 (fr) * 2001-03-09 2002-09-19 Pfizer Products Inc. Composes de benzimidazole anti-inflammatoires
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
KR100742058B1 (ko) * 2001-10-22 2007-07-23 다나베 세이야꾸 가부시키가이샤 4-이미다졸린-2-온 화합물
JP4669662B2 (ja) * 2001-10-25 2011-04-13 ユニヴァーシティー オブ コネティカット 生物活性材料、生物活性材料の製法およびその使用方法
WO2003037362A2 (fr) 2001-10-29 2003-05-08 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines homologues de mnk kinase impliquees dans la regulation de l'homeostase energetique et du metabolisme des organites
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
EP2258687B1 (fr) 2002-02-12 2012-12-26 Glaxosmithkline LLC Dérivés de nicotinamide utiles comme inhibiteurs de P38
ATE386030T1 (de) 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
KR101025675B1 (ko) 2002-04-23 2011-03-30 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
WO2004014900A1 (fr) * 2002-08-09 2004-02-19 Eli Lilly And Company Benzimidazoles et benzothiazoles utilises comme inhibiteurs de la map kinase
EP1539121A4 (fr) * 2002-08-29 2008-08-13 Scios Inc Methode pour favoriser l'osteogenese
CA2497408A1 (fr) 2002-09-03 2004-03-18 Sarvajit Chakravarty Derives de type indole servant d'inhibiteurs de la kinase p38
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
EP1560582A4 (fr) 2002-10-09 2008-03-12 Scios Inc DERIVES D'AZAINDOLE UTILISES EN TANT QU'INHIBITEURS DE LA KINASE p38
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2004113274A2 (fr) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl-urees presentant une activite d'inhibition des kinases
US7652044B2 (en) * 2003-06-03 2010-01-26 Novartis A.G. P-38 inhibitors
KR101120857B1 (ko) 2003-06-26 2012-04-12 노파르티스 아게 5원의 헤테로사이클-기재 ｐ38 키나제 억제제
US7105467B2 (en) * 2003-07-08 2006-09-12 Pharmacore, Inc. Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
ATE482205T1 (de) 2003-07-25 2010-10-15 Novartis Ag P-38-kinasehemmer
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US7880017B2 (en) * 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) * 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US7105707B2 (en) * 2003-12-17 2006-09-12 Pharmacore, Inc. Process for preparing alkynyl-substituted aromatic and heterocyclic compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
MY143245A (en) * 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
KR100793479B1 (ko) * 2004-04-28 2008-01-14 다나베 미츠비시 세이야꾸 가부시키가이샤 염증성 질환을 치료하기 위한 ｐ３８ ＭＡＰ- 키나제억제제로서의４-２-(시클로알킬아미노)피리딘-4-일-(페닐)-이미다졸린-2-온 유도체
CN101010315A (zh) * 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
JP2006182763A (ja) * 2004-12-03 2006-07-13 Daiso Co Ltd α，β−不飽和エステルの製法
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (fr) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Procédé favorisant la survie des tissus ou cellules griffées
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
EP1865959A2 (fr) * 2005-03-25 2007-12-19 Glaxo Group Limited Procede de preparation de derives pyridoý2,3-d¨pyrimidin-7-one et 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007036732A1 (fr) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo[1,2-a]pyridine à activité anti-prolifération cellulaire
DE102006001161A1 (de) * 2006-01-06 2007-07-12 Qiagen Gmbh Verfahren zum Nachweis von Cytosin-Methylierungen
CN101395158A (zh) * 2006-03-07 2009-03-25 百时美施贵宝公司 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物
AU2007235876A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
JP2010508288A (ja) * 2006-10-27 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
JP2011525184A (ja) * 2008-06-20 2011-09-15 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なトリアゾロピリジン化合物
WO2012031057A1 (fr) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms-582949 pour le traitement d'une maladie rhumatismale résistante
CN107847480B (zh) 2015-03-23 2021-06-25 墨尔本大学 呼吸性疾病的治疗
PT3619204T (pt) * 2017-05-03 2025-10-29 Tianli Biotech Pty Ltd Compostos para o tratamento de doenças respiratórias
WO2019071147A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Inhibiteurs de la kinase p38 réduisant l'expression du gène dux4 et des gènes aval pour le traitement de la fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7575099B2 (ja) 2018-11-07 2024-10-29 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処理のための新規な化合物
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US11987572B2 (en) * 2019-06-03 2024-05-21 Regents Of The University Of Minnesota Therapeutic compounds and methods of use thereof
WO2022195579A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-éthanol-amine conjuguée à l'acide hyaluronique en combinaison avec des médicaments anti-inflammatoires non stéroïdiens (ains) pour traiter ou soulager des maladies inflammatoires

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
GR75287B (fr) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0457727A1 (fr) * 1990-05-17 1991-11-21 Ciba-Geigy Ag Pesticides
US5252741A (en) * 1990-08-10 1993-10-12 Reilly Industries, Inc. Processes for the synthesis of imines, aldehydes, and unsymmetrical secondary amines
IE914327A1 (en) 1990-12-13 1992-06-17 Smithkline Beecham Corp Novel csaids
JPH06504779A (ja) 1990-12-13 1994-06-02 スミスクライン・ビーチャム・コーポレイション 新規ｃｓａｉｄｓ
AU3592493A (en) * 1992-01-13 1993-08-03 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1995003297A1 (fr) 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles actives contre les maladies transmises par la cytokine
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995009851A1 (fr) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Derives de pyrimidineamine pharmacologiquement actifs ainsi que leurs procedes de preparation
JPH08503971A (ja) * 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
KR100330553B1 (ko) * 1993-10-01 2002-11-27 노파르티스 아게 약물학적활성피리딘유도체및그의제조방법
FI972970A7 (fi) * 1995-01-12 1997-09-11 Smithkline Beecham Corp Uusia yhdisteitä
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions

Also Published As

Publication number Publication date
CA2223533A1 (fr) 1996-12-19
EP0831830B1 (fr) 2003-03-05
US6218537B1 (en) 2001-04-17
US5658903A (en) 1997-08-19
TW442481B (en) 2001-06-23
PL185515B1 (pl) 2003-05-30
AU6272696A (en) 1996-12-30
IL118544A0 (en) 1997-03-18
TR199701574T2 (xx) 1999-09-21
PE7798A1 (es) 1998-03-20
HUP9802259A3 (en) 2002-02-28
EP0831830A4 (fr) 1998-12-02
EP0831830A1 (fr) 1998-04-01
BR9608591A (pt) 1999-01-05
DE69626513D1 (en) 2003-04-10
MA24242A1 (fr) 1998-07-01
ES2194106T3 (es) 2003-11-16
DE69626513T2 (de) 2003-12-24
AU699646B2 (en) 1998-12-10
CN1192147A (zh) 1998-09-02
WO1996040143A1 (fr) 1996-12-19
IL118544A (en) 2001-08-08
PL323916A1 (en) 1998-04-27
NO975716D0 (no) 1997-12-05
ATE233561T1 (de) 2003-03-15
KR19990022574A (ko) 1999-03-25
CN1130358C (zh) 2003-12-10
NO975716L (no) 1998-02-04
NZ311403A (en) 1999-11-29
JPH11513017A (ja) 1999-11-09
HUP9802259A2 (hu) 1999-09-28
IN186434B (fr) 2001-09-01
EP1314728A1 (fr) 2003-05-28
CZ392597A3 (cs) 1998-09-16
MY114014A (en) 2002-07-31

Similar Documents

Publication Publication Date Title
DZ2043A1 (fr) Nouveaux dérivés.
ATE247470T1 (de) Neue substituierte imidazolverbindungen
PT935465E (pt) Compostos novos de imidazole substituido
MX9705296A (es) Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
TR200000059T2 (tr) Piridin türevleri
MX9805628A (es) Imidazoles novedosos substituidos con cicloalquilo.
TR199902626T2 (xx) Enflamasyon tedavisi i�in ikameli benzopiran t�revleri.
NO942618L (no) Imidazolderivater og deres anvendelse som cytokin-inhibitorer
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
SE8503680D0 (sv) Indolderivat
BR9810342A (pt) Novos compostos imidazola substituìdos
DE59702414D1 (de) Dipeptidische benzamidine als kininogenasen-inhibitoren
NO944406D0 (no) Nye 7 se inhibitorer
GB2324091A (en) Metalloproteinase inhibitors
ATE232081T1 (de) Orale zusammensetzung enthaltend perlit
ATE217619T1 (de) Endothelin-rezeptor-antagonisten
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
MX9709912A (es) Compuestos de imidazol, procedimiento para prepararlos y uso de los mismos.
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
UY24784A1 (es) Nuevos compuestos de imidazol sustituidos
ECSP961770A (es) Nuevos compuestos de imidazol 1,4,5 sustituidos
DK1105388T3 (da) N-substituerede azabicycloheptan-derivater, fremstilling og anvendelse heraf